. Author manuscript; available in PMC: 2020 Oct 14.

Published in final edited form as: J Med Chem. 2020 Sep 18;63(19):10855–10878. doi: 10.1021/acs.jmedchem.0c00545

Table 3.

Fractional Inhibitory Concentration (FIC) of a Combination of CPPB and Paclitaxel against a Patient-derived Pancreatic Adenocarcinoma PD002.^a

Entry	Combination of A and B^b	C_A and C_B (μM)^c	ΣFIC^d
1	A: CPPB	0.10	0.50
1	B: Paclitaxel	0.63	0.50
2	A: CPPB	0.10	0.13
2	B: Paclitaxel	0.16	0.13
3	A: CPPB	0.20	0.0096
3	B: Paclitaxel	0.0049	0.0096
4	A: CPPB	0.20	0.021
4	B: Paclitaxel	0.020	0.021
5	A: CPPB	0.20	0.26
5	B: Paclitaxel	0.031	0.26
6	A: CPPB	2.0	0.021
6	B: Paclitaxel	0.020	0.021
7	A: CPPB	2.0	0.037
7	B: Paclitaxel	0.039	0.037
8	A: CPPB	2.0	0.26
8	B: Paclitaxel	0.31	0.26

ΣFIC index for the wells at growth–no growth interface.

The IC₅₀ values of CPPB and paclitaxel against PD002 are 35.0 and 1.25 μM, respectively.

C_A and C_B are concentrations of A and B.

ΣFIC is the sum of fractional inhibitory concentration calculated by the equation ΣFIC = FIC_A + FIC_B = C_A/IC_50A + C_B/IC_50B. Cellular behavior of PD002 treated with paclitaxel or a combination with paclitaxel and CPPB was monitored over time by IncuCyte® live cell analysis (Supporting Information).